Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 7, 2015, Pages 785-792

  Yonchuk, John G ^a   Silverman, Edwin K ^b   Bowler, Russell P ^c   Agustí, Alvar ^d   Lomas, David A ^e   Miller, Bruce E ^a   Tal Singer, Ruth ^a   Mayer, Ruth J ^a  

^a GLAXOSMITHKLINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Biomarker; Chronic obstructive pulmonary disease; Emphysema; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ELASTIN; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; BIOLOGICAL MARKER;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; IN VIVO STUDY; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG LAVAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; LUNG; PATHOPHYSIOLOGY; PULMONARY EMPHYSEMA;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; BIOMARKERS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA;

EID: 84943328857     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201501-0137PP     Document Type: Review

References (71)

1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
2. Agusti A. The path to personalised medicine in COPD. Thorax 2014;69: 857-864.
3. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, et al.; TESRA and ECLIPSE Investigators. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:948-957.
4. Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, Kourteva G, Bitter H, Pillai SG, Visvanathan S, et al. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One 2012;7:e38629.
5. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med 2013;1:129-136.
6. Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013;25:2185-2197.
7. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
8. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 2012;249: 158-175.
9. Koch M, Chitayat S, Dattilo BM, Schiefner A, Diez J, Chazin WJ, Fritz G. Structural basis for ligand recognition and activation of RAGE. Structure 2010;18:1342-1352.
10. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A, Postina R. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008;283:35507-35516.
11. Mukherjee TK, Mukhopadhyay S, Hoidal JR. Implication of receptor for advanced glycation end product (RAGE) in pulmonary health and pathophysiology. Respir Physiol Neurobiol 2008;162:210-215.
12. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) 2009;87:235-247.
13. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008;22:1572-1580.
14. Julian MW, Shao G, Vangundy ZC, Papenfuss TL, Crouser ED. Mitochondrial transcription factor A, an endogenous danger signal, promotes TNFα release via RAGE- and TLR9-responsive plasmacytoid dendritic cells. PLoS One 2013;8:e72354.
15. Hudson BI, Kalea AZ, Del Mar Arriero M, Harja E, Boulanger E, D'Agati V, Schmidt AM. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and CDC42. J Biol Chem 2008;283: 34457-34468.
16. ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-17814.
17. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, et al. Diabetesassociated sustained activation of the transcription factor nuclear factor-κB. Diabetes 2001;50:2792-2808.
18. Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth PP, Martin E, Weigand MA. Bench-to-bedside review: the inflammation perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008;12:201.
19. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion. Diabetes 2001;50:1495-1504.
20. Reynolds PR, Stogsdill JA, Stogsdill MP, Heimann NB. Up-regulation of receptors for advanced glycation end-products by alveolar epithelium influences cytodifferentiation and causes severe lung hypoplasia. Am J Respir Cell Mol Biol 2011;45:1195-1202.
21. Myint K-M, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006;55:2510-2522.
22. Al-Robaiy S, Weber B, Simm A, Diez C, Rolewska P, Silber R-E, Bartling B. The receptor for advanced glycation end-products supports lung tissue biomechanics. Am J Physiol Lung Cell Mol Physiol 2013;305:L491-L500.
23. Stogsdill MP, Stogsdill JA, Bodine BG, Fredrickson AC, Sefcik TL, Wood TT, Kasteler SD, Reynolds PR. Conditional overexpression of receptors for advanced glycation end-products in the adult murine lung causes airspace enlargement and induces inflammation. Am J Respir Cell Mol Biol 2013;49:128-134.
24. Reynolds PR, Kasteler SD, Schmitt RE, Hoidal JR. Receptor for advanced glycation end-products signals through Ras during tobacco smoke-induced pulmonary inflammation. Am J Respir Cell Mol Biol 2011;45:411-418.
25. Robinson AB, Johnson KD, Bennion BG, Reynolds PR. RAGE signaling by alveolar macrophages influences tobacco smoke-induced inflammation. Am J Physiol Lung Cell Mol Physiol 2012;302: L1192-L1199.
26. Ha CH, Kim S, Chung J, An SH, Park S, Choi D, Kwon K. Inhibitory effect of soluble RAGE in disturbed flow-induced atherogenesis. Int J Mol Med 2013;32:373-380.
27. Miller AL, Sims GP, Brewah YA, Rebelatto MC, Kearley J, Benjamin E, Keller AE, Brohawn P, Herbst R, Coyle AJ, et al. Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection. J Infect Dis 2012;205:1311-1320.
28. Jeong SJ, Lim BJ, Park S, Choi D, Kim HW, Ku NS, Han SH, Kim CO, Choi JY, Song YG, et al. The effect of sRAGE-Fc fusion protein attenuates inflammation and decreases mortality in a murine cecal ligation and puncture model. Inflamm Res 2012;61:1211-1218.
29. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Hörig H, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46:2916-2924.
30. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-1137.
31. Wu L, Ma L, Nicholson LFB, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 2011;105:329-336.
32. Gopal P, Reynaert NL, Scheijen JLJM, Engelen L, Schalkwijk CG, Franssen FME, Wouters EFM, Rutten EPA. Plasma advanced glycation end-products and skin autofluorescence are increased in COPD. Eur Respir J 2014;43:430-438.
33. Hou C, Zhao H, Liu L, Li W, Zhou X, Lv Y, Shen X, Liang Z, Cai S, Zou F. High mobility group protein B1 (HMGB1) in asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med 2011;17:807-815.
34. Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, Dombret MC, Sims GP, Kolbeck R, Coyle AJ, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:917-927.
35. Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG, Wark PAB. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 2012;39:721-729.
36. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, Franceschini N, van Durme YMTA, Chen T-H, Barr RG, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2010; 42:45-52.
37. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, Zhao JH, Ramasamy A, Zhai G, Vitart V, et al.; Wellcome Trust Case Control Consortium; NSHD Respiratory Study Team. Genome-wide association study identifies five loci associated with lung function. Nat Genet 2010;42:36-44.
38. Young RP, Hay BA, Hopkins RJ. Does RAGE protect smokers from COPD? Eur Respir J 2011;38:743-744, author reply 744.
39. Castaldi PJ, Cho MH, San José Estépar R, McDonald M-LN, Laird N, Beaty TH, Washko G, Crapo JD, Silverman EK; COPDGene Investigators. Genome-wide association identifies regulatory loci associated with distinct local histogram emphysema patterns. Am J Respir Crit Care Med 2014;190:399-409.
40. Manichaikul A, Hoffman EA, Smolonska J, Gao W, Cho MH, Baumhauer H, Budoff M, Austin JHM, Washko GR, Carr JJ, et al. Genome-wide study of percent emphysema on computed tomography in the general population: the Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. Am J Respir Crit Care Med 2014;189:408-418.
41. Cho MH, Castaldi PJ, Hersh CP, Hobbs BD, Barr RG, Tal-Singer R, Bakke P, Gulsvik A, San Jose Estepar R, Van Beek EJ, et al.; NETT Genetics Investigators; ECLIPSE Investigators; COPDGene Investigators. A genome-wide association study of emphysema and airway quantitative imaging phenotypes. Am J Respir Crit Care Med 2015;192:559-569.
42. Gaens KHJ, Ferreira I, van der Kallen CJH, van Greevenbroek MMJ, Blaak EE, Feskens EJM, Dekker JM, Nijpels G, Heine RJ, 't Hart LM, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 2009;94:5174-5180.
43. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011;37:516-522.
44. Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011;12:37.
45. Gopal P, Rutten EPA, Dentener MA, Wouters EFM, Reynaert NL. Decreased plasma sRAGE levels in COPD: influence of oxygen therapy. Eur J Clin Invest 2012;42:807-814.
46. Iwamoto H, Gao J, Koskela J, Kinnula V, Kobayashi H, Laitinen T, Mazur W. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J 2014;43:421-429.
47. Iwamoto H, Gao J, Pulkkinen V, Toljamo T, Nieminen P, Mazur W. Soluble receptor for advanced glycation end-products and progression of airway disease. BMC Pulm Med 2014;14:68.
48. Carolan BJ, Hughes G, Morrow J, Hersh CP, O'Neal WK, Rennard S, Pillai SG, Belloni P, Cockayne DA, Comellas AP, et al. The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respir Res 2014; 15:127.
49. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-135.
50. Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 2008;283:27255-27269.
51. Park SJ, Kleffmann T, Hessian PA. The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant. J Biol Chem 2011;286: 21384-21392.
52. Zong H, Madden A, Ward M, Mooney MH, Elliott CT, Stitt AW. Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem 2010;285:23137-23146.
53. Waseda K, Miyahara N, Taniguchi A, Kurimoto E, Ikeda G, Koga H, Fujii U, Yamamoto Y, Gelfand EW, Yamamoto H, et al. Emphysema requires the receptor for advanced glycation end products triggering on structural cells. Am J Respir Cell Mol Biol 2015; 52: 482-491.
54. Sambamurthy N, Leme AS, Oury TD, Shapiro SD. The receptor for advanced glycation end products (RAGE) contributes to the progression of emphysema in mice. PLoS One 2015;10:e0118979.
55. Beucher J, Boëlle P-Y, Busson P-F, Muselet-Charlier C, Clement A, Corvol H; French CF Gene Modifier Study Investigators. AGER-429T/C is associated with an increased lung disease severity in cystic fibrosis. PLoS One 2012;7:e41913.
56. Gopal P, Reynaert NL, Scheijen JLJM, Schalkwijk CG, Franssen FME, Wouters EFM, Rutten EP. Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. Respir Res 2014; 15:24.
57. Boschetto P, Campo I, Stendardo M, Casimirri E, Tinelli C, Gorrini M, Ceconi C, Fucili A, Potena A, Papi A, et al. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest 2013;43:562-569.
58. Rebholz CM, Astor BC, Grams ME, Halushka MK, Lazo M, Hoogeveen RC, Ballantyne CM, Coresh J, Selvin E. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant 2015;30:77-83.
59. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007;23:368-371.
60. Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J, Astor BC. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121.
61. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005;7:R817-R824.
62. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, Clissa C, Ciabattoni G, Consoli A, Davì G. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007;43:511-518.
63. Tan KCB, Chow WS, Tso AWK, Xu A, Tse HF, Hoo RLC, Betteridge DJ, Lam KSL. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 2007;50:1819-1825.
64. Santilli F, Bucciarelli L, Noto D, Cefalù AB, Davì V, Ferrante E, Pettinella C, Averna MR, Ciabattoni G, Davì G. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007;43:1255-1262.
65. Center for Drug Evaluation and Research (CDER), Food and Drug Administration, U.S. Department of Health and Human Services. Guidance for industry and FDA staff: qualification process for drug development tools [accessed 2015 Jan 10]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm230597.pdf
66. Center for Veterinary Medicine (CVM), Drug Evaluation and Research (CDER), Food and Drug Administration, U.S. Department of Health and Human Services. Guidance for industry: bioanalytical method validation [accessed 2015 Jan 10]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf
67. Chen Y-S, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009;11:R39.
68. Mahajan N, Dhawan V. Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases. Int J Cardiol 2013;168:1788-1794.
69. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007;8:1138-1143.
70. Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AMM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol 2014;14:12.
71. Six-month safety and efficacy study of TTP488 in patients with type 2 diabetes and persistent albuminuria - full text view. ClinicalTrials.gov NCT00287183 [received 2006 Jan 20; updated 2009 Sept; accessed 2014 Nov 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT00287183?term=TTP488&rank=1